Use of flibanserin in the treatment of obesity

• US 10,335,407 B2
• Filed: 07/31/2017
• Issued: 07/02/2019
• Est. Priority Date: 08/03/2005
• Status: Active Grant

• Current Assignee: Sprout Pharmaceuticals, Inc. (Sprout2, Inc.)
• Original Assignee: Sprout Pharmaceuticals, Inc. (Sprout2, Inc.)
• Inventors: Ceci, Angelo, Schindler, Marcus
• Primary Examiner(s): Weddington, Kevin E
• Application Number:
  US15/664,163
• Publication Number:
  US 20180015084A1
• Time in Patent Office: 701 Days
• Field of Search: 51426622, 514449, 514646
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/13 Amines A61K31/04 takes precedence
• CPC Class Codes: A61K 31/131 acyclic
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/335 having oxygen as the only ring hetero atom, e.g. fungichromin
• CPC Class Codes: A61K 31/34 having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
• CPC Class Codes: A61K 31/365 Lactones
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives

Abstract

The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.

Claims

1. A pharmaceutical composition comprising a) an active substance being not flibanserin, selected from the group comprising pioglitazone or a pharmaceutical acceptable salt thereof, troglitazone, rosiglitazone or a pharmaceutical acceptable salt thereof, JTT-501, GI-262570, MCC-555, YM-440, DRF-2593, BM-13-1258, KRP-297, R-119702, GW-1929, tolbutamide, chloropropamide, tolazamide, acetohexamide, glyclopyramide, an ammonium salt of glyclopyramide, glibenclamide, gliclazide, glimepiride, repaglinide, nateglinide, mitiglinide, JTT-608, metformin, bovine insulin, porcine insulin, semisynthetic human insulin, genetically-engineered human insulin, acarbose, voglibose, miglitol, emiglitate, AJ-9677, BMS-196085, SB-226552, AZ40140, tolrestat, epalrestat, imirestat, zenarestat, SNK-860, zopolrestat, ARI-50i, AS-3201, NGF, LY-333531, LAF237, MK431, 815541, 823093, 825964, liraglutide, exenatide, AVE-2268, T-1095, mazindol, baiamine, NGD-95-1, lipstatin, rimonabant, phenylpropanolamine, ephedrine, pseudroephedrine, dexfenfluramine, fenfluramine, BVT.933, APD356, bromocriptine, pramipexol, dehydroepiandrosterone, exendin, AC 2993, CJC-1131, ZP10, GRT0203Y, captopril, enalapril, alacepril, delapril, lisinopril, imidapril, benazepril, cilazapril, temocapril, trandolapril, manidipine, nifedipine, amlodipine, efonidipine, nicardipine, levcromakalim, L-27152, AL0671, NIP-121, telmisartan, losartan, candesartan cilexetil, valsartan, irbesartan, CS-866, E4177, pravastatin or a pharmaceutical acceptable salt thereof, simvastatin or a pharmaceutical acceptable salt thereof, lovastatin or a pharmaceutical acceptable salt thereof, atorvastatin or a pharmaceutical acceptable salt thereof, fluvastatin or a pharmaceutical acceptable salt thereof, lipantil or a pharmaceutical acceptable salt thereof, cerivastatin or a pharmaceutical acceptable salt thereof, itavastatin or a pharmaceutical acceptable salt thereof, ZD-4522 or a pharmaceutical acceptable salt thereof, bezafibrate, clinofibrate, clofibrate, simfibrate, or mixtures thereof and b) flibanserin, optionally in form of the free base, and/or a pharmacologically pharmaceutically acceptable acid addition salt thereof.

2. A pharmaceutical composition according to claim 1, wherein flibanserin is in the form of a pharmacologically acceptable acid addition salt thereof selected from the salts formed by the acids selected from the group consisting of succinic acid, hydrobromic acid, acetic acid, fumaric acid, maleic acid, methanesulphonic acid, lactic acid, phosphoric acid, hydrochloric acid, sulphuric acid, tartaric acid, citric acid, and mixtures thereof.

3. A pharmaceutical composition according to claim 1, wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with succinic acid.

4. A pharmaceutical composition according to claim 1, wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with hydrobromic acid.

5. A pharmaceutical composition according to claim 1, wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with acetic acid.

6. A pharmaceutical composition according to claim 1, wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with fumaric acid.

7. A pharmaceutical composition according to claim 1, wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with maleic acid.

8. A pharmaceutical composition according to claim 1, wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with methanesulfonic acid.

9. A pharmaceutical composition according to claim 1, wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with lactic acid.

10. A pharmaceutical composition according to claim 1, wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with phosphoric acid.

11. A pharmaceutical composition according to claim 1, wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with hydrochloric acid.

12. A pharmaceutical composition according to claim 1, wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with sulphuric acid.

13. A pharmaceutical composition according to claim 1, wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with tartaric acid.

14. A pharmaceutical composition according to claim 1, wherein flibanserin is in the form of a pharmaceutically acceptable acid addition salt thereof and wherein the salt is formed with citric acid.

15. A pharmaceutical composition according to claim 1, wherein the composition contains between 0.01 to 400 mg of flibanserin.

16. A pharmaceutical composition according to claim 1, wherein the composition contains between 2.0 to 200 mg of flibanserin.

17. A pharmaceutical composition according to claim 1, wherein the composition contains 100 mg of flibanserin.